//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Professor of Integrative Physiology @University of Helsinki and Head of Atherosclerosis Research Laboratory @ Wihuri Research Institute, Helsinki, Finland linkedin.com/in/katioorni orcid.org/0000-0002-9525-0250 (Orcid ) www.wri.fi
katioorni.bsky.social








Loading...
Paul Ridker giving the Anitschkow lecture of #EASCongress2025
Here we go #EASCongress2025
Our latest study, published in @insight.jci.org , shows how high-dose icosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA) remodels circulating lipoproteins and reduces cardiovascular risk markers in healthy individuals. insight.jci.org/articles/vie...
With just a few days left to register for #EASCongress2025, this is your opportunity to be part of vital conversations and gain insights from leading experts in the field of atherosclerosis. Join us for an enriching and thought-provoking experience 👉 bit.ly/3UYJAKF
May 4, 2025
May 4, 2025
#EASCongress is all about learning and meeting people. This year, we’re focusing even more on the networking part. Make sure to download our app - we’re launching a great new feature that helps you connect with others who share your interests, before, during, and after the event.
Check our newest paper on how IPE (EPA-precursor) supplementation rapidly induces lipoprotein remodeling, and its impact on CVD risk markers in normolipidemic individuals: insight.jci.org/articles/vie... @katioorni.bsky.social #MedSky #CVD #Atherosclerosis #ScienceSky #Lipoproteins
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
8mo
Apr 16, 2025
New study from Kati Öörni’s lab @katioorni.bsky.social at #WRIHelsinki on the effect of icosapent ethyl (IPE) on circulating lipoproteins and their pro-atherogenic properties.👇
Apr 9, 2025
8mo
May 8, 2025
This paper made it to the top of our readership list: Icosapent ethyl–induced lipoprotein remodeling and its impact on cardiovascular disease risk markers in normolipidemic individuals @martinalorey.bsky.social @katioorni.bsky.social insight.jci.org/articles/vie...
7mo
katioorni.bsky.social
katioorni.bsky.social
7mo
katioorni.bsky.social
European Atherosclerosis Society
European Atherosclerosis Society
Martina Lorey
Federica Fogacci
Wihuri Research Institute
Our latest study, published in @insight.jci.org , shows how high-dose icosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA) remodels circulating lipoproteins and reduces cardiovascular risk markers in healthy individuals. insight.jci.org/articles/vie...
8mo
katioorni.bsky.social
JCI insight
insight.jci.org
JCI Insight - Icosapent ethyl–induced lipoprotein remodeling and its impact on cardiovascular disease risk markers in normolipidemic individuals